MRK Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

121.070

Open

119.285

VWAP

119.77

Vol

8.35M

Mkt Cap

295.77B

Low

118.600

Amount

999.54M

EV/EBITDA(TTM)

10.87

Total Shares

2.47B

EV

330.60B

EV/OCF(TTM)

20.07

P/S(TTM)

4.61

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Show More

Events Timeline

(ET)

2026-03-29

12:00:00

Merck Announces Phase 2 Study Results for Winrevair

2026-03-26 (ET)

2026-03-26

16:10:00

BMO Capital Downgrades Terns Pharmaceuticals to Market Perform with $53 Price Target

2026-03-26

08:10:00

Agilent Receives FDA Approval for PD-L1 IHC 22C3 as KEYTRUDA Companion Diagnostic

2026-03-25 (ET)

2026-03-25

16:30:00

Major Averages Rise on U.S. Iran Peace Plan

2026-03-25

16:20:00

TD Cowen Downgrades Terns Pharmaceuticals to Hold, Price Target $53

2026-03-25

12:10:00

U.S. Offers Iran 15-Point Peace Plan, Oil Prices Drop

2026-03-25

11:30:00

William Blair Says Merck's Offer Undervalues Terns' TERN-701

2026-03-25

11:20:00

William Blair Says Merck's $116.37 Offer Undervalues Terns

2026-03-25

11:20:00

RBC: Investors Disappointed by Merck's Terns Acquisition Premium

News

moomoo

PinnedMERCK & CO INC - WINREVAIR TO MOVE FORWARD INTO PHASE 3 REGISTRATION TRIAL FOR CPCPH-HFPEF

moomoo

PinnedMERCK & CO: COMPREHENSIVE EVIDENCE FROM HEMODYNAMIC, FUNCTIONAL, ECHOCARDIOGRAPHIC, AND CLINICAL MEASURES BACKS FURTHER DEVELOPMENT OF WINREVAIR

moomoo

PinnedMERCK & CO INC - WINREVAIR ACHIEVES PRIMARY GOAL IN PHASE 2 CADENCE STUDY

moomoo

PinnedEncouraging Phase 2 Cadence Trial Results Confirm WinrevaIR™ (Sotatercept-CSRK) as a Promising Treatment for Adults with Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

NASDAQ.COM

03-29NASDAQ.COM

Merck Reports Phase 2 Study Results for WINREVAIR

Newsfilter

03-29Newsfilter

Merck's WINREVAIR Achieves Key Clinical Trial Milestone

16 Analyst Rating

Wall Street analysts forecast MRK stock price to rise

11 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

95.00

Averages

119.53

High

139.00

Current: 0.000

Low

95.00

Averages

119.53

High

139.00

Citi

Neutral

maintain

$120 -> $125

AI Analysis

2026-03-20

Reason

Citi

Price Target

$120 -> $125

AI Analysis

2026-03-20

maintain

Neutral

Reason

Citi raised the firm's price target on Merck to $125 from $120 and keeps a Neutral rating on the shares.

Wells Fargo

NULL -> Overweight

upgrade

$135 -> $150

2026-03-12

Reason

Wells Fargo

Price Target

$135 -> $150

2026-03-12

upgrade

NULL -> Overweight

Reason

Wells Fargo raised the firm's price target on Merck to $150 from $135 and keeps an Overweight rating on the shares. The firm thinks Sac-TMT could become the best-in-class TROP2 antibody-drug conjugate and replace chemo in multiple lung, breast, and gynecologic indications.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MRK

Unlock Now

Valuation Metrics

The current forward P/E ratio for Merck & Co Inc (MRK.N) is 12.32, compared to its 5-year average forward P/E of 17.02. For a more detailed relative valuation and DCF analysis to assess Merck & Co Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

17.02

Current PE

12.32

Overvalued PE

32.15

Undervalued PE

1.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

11.55

Current EV/EBITDA

8.86

Overvalued EV/EBITDA

16.71

Undervalued EV/EBITDA

6.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.07

Current PS

3.95

Overvalued PS

4.67

Undervalued PS

3.47

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 51 candidates

Market Cap: >= 30.00BPe Ttm: 8 - 25List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Is Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

JPMorgan Chase & Co

762.83B

Johnson & Johnson

579.15B

Procter & Gamble Co

333.48B

Coca-Cola Co

325.87B

Merck & Co Inc

295.77B

Morgan Stanley

251.50B

Intellectia · 48 candidates

Market Cap: >= 30.00BMarket Cap Category: large, megaRevenue 5yr Cagr: >= 8Pe Ttm: 10 - 25List Exchange: XNYSReturn On Equity: >= 12.0%

Ticker

Name

Market Cap$

JPMorgan Chase & Co

762.83B

Merck & Co Inc

295.77B

Morgan Stanley

251.50B

Goldman Sachs Group Inc

236.85B

UnitedHealth Group Inc

235.11B

Royal Bank of Canada

220.86B

best stock buy right now

Intellectia · 23 candidates

Eps 5yr Cagr: >= 10Pe Ttm: 10 - 35Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDXOne Month Predict Return: >= 0.0%

Ticker

Name

Market Cap$

Ball Corp

15.87B

FedEx Corp

83.40B

Merck & Co Inc

294.04B

Applied Materials Inc

268.68B

Snap-On Inc

18.84B

Eaton Corporation PLC

138.55B

top stocks in health sector

Intellectia · 38 candidates

Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%

Ticker

Name

Market Cap$

Eli Lilly and Co

866.87B

AbbVie Inc

364.65B

AstraZeneca PLC

293.00B

Merck & Co Inc

282.35B

UnitedHealth Group Inc

254.55B

Amgen Inc

188.63B

Best place to in vest $10,000.00

Intellectia · 81 candidates

Market Cap: >= 20.00BRegion: USNet Margin: >= 10.00Revenue 5yr Cagr: >= 5Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEIs Index Component: GSPC

Ticker

Name

Market Cap$

Meta Platforms Inc

1.53T

JPMorgan Chase & Co

776.66B

Micron Technology Inc

500.03B

Bank of America Corp

337.38B

Coca-Cola Co

325.18B

Merck & Co Inc

282.35B

What should i buy right now?

Intellectia · 57 candidates

Market Cap: >= 20.00BPe Ttm: 10 - 35List Exchange: XNYS, XNASReturn On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Alphabet Inc

3.71T

Johnson & Johnson

571.52B

Micron Technology Inc

519.68B

Coca-Cola Co

326.99B

Caterpillar Inc

322.73B

Cisco Systems Inc

306.51B

what stock should I buy today

Intellectia · 52 candidates

Pe Ttm: 12 - 30Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Johnson & Johnson

573.51B

Micron Technology Inc

519.64B

Coca-Cola Co

333.92B

Cisco Systems Inc

313.11B

Merck & Co Inc

286.48B

Linde PLC

228.94B

are there any double bottoms about to form?

Intellectia · 165 candidates

Market Cap: >= 500.00MRegion: USVolume: >= 0Market Cap Category: mid, small, micro, large, megaRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossAboveMA5Month Price Change Pct: $-20.00 - $0.00Support Resistance Relationship: PriceAroundSupport

Ticker

Name

Market Cap$

Merck & Co Inc

286.48B

Morgan Stanley

250.61B

Goldman Sachs Group Inc

239.49B

Walt Disney Co

177.68B

Analog Devices Inc

153.13B

Sumitomo Mitsui Financial Group, Inc

125.60B

investment advice, stock recommendations.

Intellectia · 72 candidates

Dividend Yield Ttm: 1 - 4Price: $20.00 - $150.00Analyst Consensus: Strong Buy, Moderate BuyPe Ttm: 8 - 30Is Index Component: GSPC

Ticker

Name

Market Cap$

Bank of America Corp

339.31B

Coca-Cola Co

333.92B

Cisco Systems Inc

313.11B

Merck & Co Inc

286.48B

Abbott Laboratories

192.82B

Nextera Energy Inc

192.79B

Whales Holding MRK

ALPS Advisors, Inc.

FengHe Fund Management Pte. Ltd.

Old Republic International Corporation

Journey Strategic Wealth LLC

Smead Capital Management, Inc.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Merck & Co Inc (MRK) stock price today?

The current price of MRK is 119.63 USD — it has increased 0.59

What is Merck & Co Inc (MRK)'s business?

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

What is the price predicton of MRK Stock?

Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is119.53 USD with a low forecast of 95.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Merck & Co Inc (MRK)'s revenue for the last quarter?

Merck & Co Inc revenue for the last quarter amounts to 16.40B USD, increased 4.97

What is Merck & Co Inc (MRK)'s earnings per share (EPS) for the last quarter?

Merck & Co Inc. EPS for the last quarter amounts to 1.19 USD, decreased -19.59

How many employees does Merck & Co Inc (MRK). have?

Merck & Co Inc (MRK) has 75000 emplpoyees as of March 30 2026.

What is Merck & Co Inc (MRK) market cap?

Today MRK has the market capitalization of 295.77B USD.